Table 3.
Correlation between RCCEP and tumor response.
| Items | Number of patients | ORR | Difference in ORR | ||||
|---|---|---|---|---|---|---|---|
| Total, N | With RCCEP, n (%) | Without RCCEP, n (%) | With RCCEP, % (95% CI) |
Without RCCEP, % (95% CI) |
With RCCEP − without RCCEP, % (95% CI) | p Value | |
| Camrelizumab monotherapy | |||||||
| HCC | 217 | 145 (66.8%) | 72 (33.2%) | 18.6% (12.6–25.9) | 4.2% (0.9–11.7) | 14.4% (6.6–22.3) | 0.0038 |
| EC | 228 | 182 (79.8%) | 46 (20.2%) | 25.3% (19.1–32.2) | 0.0% (0.0–6.3) | 25.3% (19.0–31.6) | 0.0001 |
| All | 670 | 516 (77.0%) | 154 (23.0%) | 23.8% (20.2–27.8) | 1.9% (0.4–5.6) | 21.9% (17.6–26.2) | <0.0001 |
| Camrelizumab plus apatinib | |||||||
| PLC | 28 | 6 (21.4%) | 22 (78.6%) | 33.3% (4.3–77.7) | 4.5% (0.1–22.8) | 28.8% (−9.9 to 67.5) | 0.0472 |
| Extensive SCLC | 59 | 7 (11.9%) | 52 (88.1%) | 57.1% (18.4–90.1) | 30.8% (18.7–45.1) | 26.4% (−12.4 to 65.1) | 0.1700 |
| GC/GEJC | 19 | 0 (0.0%) | 19 (100.0%) | / | 10.5% (1.3–33.1) | / | / |
| HCC | 190 | 57 (30.0%) | 133 (70.0%) | 49.1% (35.6–62.7) | 21.8% (15.1–29.8) | 27.3% (12.6–42.1) | 0.0002 |
| All | 296 | 70 (23.6%) | 226 (76.4%) | 48.6% (36.4–60.8) | 21.2% (16.1–27.2) | 27.3% (14.5–40.2) | <0.0001 |
| Camrelizumab plus chemotherapy | |||||||
| NSCLC | 205 | 159 (77.6%) | 46 (22.4%) | 69.8% (62.0–76.8) | 28.3% (16.0–43.5) | 41.6% (26.7–56.4) | <0.0001 |
| NPC | 134 | 71 (53.0%) | 63 (47.0%) | 98.6% (92.4–100.0) | 73.0% (60.3–83.4) | 25.6% (14.3–36.9) | <0.0001 |
| All | 339 | 230 (67.8%) | 109 (32.2%) | 78.7% (72.8–83.8) | 54.1% (44.3–63.7) | 24.6% (13.8–35.3) | <0.0001 |
Mantel–Haenszel χ2 test was used to calculate the p value.
EC, esophageal cancer; GC/GEJC, gastric or gastroesophageal junction cancer; HCC, hepatocellular carcinoma; NPC, nasopharyngeal carcinoma; NSCLC, non-small-cell lung cancer; ORR, objective response rate; PLC, primary liver cancer; RCCEP, reactive cutaneous capillary endothelial proliferation; SCLC, small-cell lung cancer.